var data={"title":"Hemin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hemin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6306?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hemin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hemin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=hemin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hemin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178696\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Panhematin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178703\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Modifiers;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178697\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Porphyria:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> IV: 1 to 4 mg/kg/day for 3 to 14 days; may be repeated no earlier than every 12 hours (for severe cases); maximum: 6 mg/kg per 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Usual regimen:</i> IV: 3 to 4 mg/kg once daily for 4 days (Anderson 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053516\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hemin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hemin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Porphyria:</b> Adolescents &ge;16 years: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178698\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897444\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897445\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178691\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Panhematin: 313 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Panhematin: 350 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178683\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053517\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV infusion only. Infuse over at least 30 minutes through a 0.45 micron or smaller filter. Administer through a large vein or central line to prevent phlebitis. After infusion, flush with 100 mL NS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178692\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Porphyria:</b> Management of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Before hemin administration, the manufacturer recommends an appropriate period of carbohydrate loading (ie, 400 g glucose/day for 1 to 2 days). However, glucose may be appropriate for mild cases only and hemin should be initiated early for most acute attacks, although glucose may be utilized while awaiting hemin therapy (Anderson 2005). For moderate to severe attacks, immediate hemin treatment is recommended. Porphyria attacks may progress to a point of irreversible neuronal damage; hemin therapy is intended to prevent an attack from reaching a critical stage of neuronal degeneration; hemin is not effective in repairing neuronal damage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178688\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Pyrexia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic: Leukocytosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Phlebitis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Coagulopathy, fibrin split products increased, hematocrit decreased, hypofibrogenemia, prothrombin time increased, partial thromboplastin time increased, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178694\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to hemin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053197\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulation: Transient, mild anticoagulation effects have been observed, although the extent and duration of hypocoagulation have not been determined. Avoid concurrent anticoagulation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iron overload: Repeat administration cycles may result in iron overload; monitor iron and serum ferritin; consider iron chelation therapy if elevated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Asymptomatic oliguria, increased nitrogen retention and reversible renal shutdown has been observed (case report) at a single dose above the recommended dose. Recommended dosage guidelines should be followed; worsening of renal function has not been observed with the recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Clinical benefit depends on prompt administration. Porphyria attacks may progress to result in irreversible neuronal damage. Hemin is intended to prevent attacks from becoming critical; hemin is not effective in repairing neuronal damage resulting from attacks. After discontinuation, although remission may be prolonged, acute porphyria symptoms generally return.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease, including a theoretical risk of Creutzfeldt-Jakob disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to Recordati Rare Diseases at 1-888-575-8344.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Although the manufacturer's labeling recommends initial therapy with glucose (ie, 400 g/day for 1 to 2 days), glucose may be appropriate for mild cases only and hemin should be initiated early for most acute attacks, although glucose may be utilized while awaiting hemin therapy (Anderson 2005). For moderate to severe attacks, immediate hemin treatment is recommended. Follow recommended dosage; excessive single doses have resulted in reversible renal shutdown, with asymptomatic oliguria and increased nitrogen retention. Administer through a large vein (or central line) to prevent phlebitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299437\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220760\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8970&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Hemin may enhance the anticoagulant effect of Anticoagulants. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May diminish the therapeutic effect of Hemin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Hemin.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053194\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of hemin for acute attacks of porphyria during pregnancy has been described (Anderson 2005; Marsden 2010; Stein 2013). Avoid use in severe pre-eclampsia (theoretical risk of potentiation of the coagulation disorder).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570872\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if hemin is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053519\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to treatment: Urinary levels of porphobilinogen (PBG), delta aminolevulinic acid (ALA), and total porphyrin. (<b>Note:</b> Classical Watson-Schwartz or Hoesch tests are less reliable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">During treatment: Urinary levels of ALA, uroporphyrin (UPG), PBG, and coproporphyrin; monitor iron and serum ferritin (if receiving multiple hemin doses). Monitor serum creatinine and electrolytes (including magnesium) daily; monitor vital capacity, neurologic status, including proximal muscle strength, monitor for bladder retention, monitor for signs/symptoms of progressing porphyria (Anderson 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3053514\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Limits hepatic and/or marrow porphyrin synthesis by inhibiting synthesis of aminolevulinic acid synthase, the enzyme that regulates the porphyrin/heme pathway</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45062654\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Clinical improvement begins within 1 to 2 days if hemin is initiated early (Anderson 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323180\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Panhematin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">350 mg (1): $8,938.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4041594\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Human Hemin Orphan Europe (PL);</li>\n      <li>Normosang (AT, CH, CZ, DK, EE, ES, FI, GB, HR, IE, JP, LT, MT, NO, PT, SE, SI, SK);</li>\n      <li>Panhematin (AU, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias [published correction appears in <i>Ann Intern Med</i>. 2015;143(4):316]. <i>Ann Intern Med</i>. 2005;142(6):439-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hemin-drug-information/abstract-text/15767622/pubmed\" target=\"_blank\" id=\"15767622\">15767622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsden JT, Rees DC. A retrospective analysis of outcome of pregnancy in patients with acute porphyria. <i>J Inherit Metab Dis</i>. 2010;33(5):591-596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hemin-drug-information/abstract-text/20567908/pubmed\" target=\"_blank\" id=\"20567908\">20567908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Panhematin (hemin) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stein P, Badminton M, Barth J, et al; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. <i>Ann Clin Biochem</i>. 2013;50(pt 3):217-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hemin-drug-information/abstract-text/23605132/pubmed\" target=\"_blank\" id=\"23605132\">23605132</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8970 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178696\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178703\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178697\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3053516\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178698\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897444\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897445\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178691\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178683\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3053517\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178692\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178688\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178694\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3053197\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299437\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220760\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3053194\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16570872\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3053519\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3053514\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45062654\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323180\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4041594\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8970|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hemin-patient-drug-information\" class=\"drug drug_patient\">Hemin: Patient drug information</a></li><li><a href=\"topic.htm?path=hemin-pediatric-drug-information\" class=\"drug drug_pediatric\">Hemin: Pediatric drug information</a></li></ul></div></div>","javascript":null}